

## Type 2 Diabetes - Chronic Kidney Disease

CKD is eGFR < 60ml/min or kidney damage for ≥ 3 months (e.g. urine sediment, abnormal imaging, or albuminuria (UACR < 30mg/g = nl, 30-300 = micro, >300 = macro))

### Stages of Chronic Kidney Disease (CKD)

	1	2	3	4	5
eGFR	> 60	> 60	30-59	15-29	< 15 ml/min/1.73m <sup>2</sup>

**Markers of progression:** decreasing eGFR, increasing albuminuria, poor BP control

### Workup of CKD and to r/o non-diabetes causes

CMP, UA, UACR, Uric Acid, Phos, CBC, ANA, RF, C3, C4, HepB sAg, HepC Ab, dilated retinal exam, and renal U/S; if pat >40 yrs & UACR is pos then check SPEP and UPEP

### Referrals

Nephrologist: When eGFR < 30 or sooner if unsure of etiology or problems  
 Nutrition: Refer to RD for consult (protein, Na+, K+, PO4, fluids, saturated fat)

### Managing Complications of CKD – Stages 3-5

<b>Acidosis</b>		
If CO2 < 22mmol/L	Start sodium bicarbonate 325-650mg (1-2 tabs) TID-QID	Goal: CO2 ≥ 22mmol/L
<b>Anemia</b>		
Check Hb at least yearly: Anemia = Hb <13.5 g/dL adult men, <12 g/dL adult women; r/o B12/folate deficiency, GI blood loss, other causes		
<b>Baseline Labs:</b> Ferritin, transferrin % sat, iron studies (Fe, % Sat, TIBC), CBC+diff		
Start oral iron therapy if ferritin/iron studies low		
Ferrous Sulfate (FeSO4) 325mg daily to TID		
Consider docusate 100mg BID to reduce constipation		
<b>Monitor ferritin to avoid iron overload</b>		
Consider IV iron or blood transfusion if needed		
Safety of erythropoiesis stimulating agents (ESA) unclear; reserve for patients on dialysis, pending renal transplant, or Hb < 9 with symptoms unresponsive to treatment above		
<b>Blood Pressure</b>		
<b>Most effective CKD intervention:</b> BP goal <130/80; continue ACEI/ARB (watch K+)		
<b>Cardiovascular Disease (CVD)</b>		
CVD: CKD increases CVD risk – patients on aspirin (if no contraindications)		
Achieve lipid targets, encourage tobacco cessation		
<b>Diabetes</b>		
Blood sugar control—as renal fxn declines pts' BGs often improve—titrate meds down as needed; Caution setting an A1c target <7% if advanced CKD or CVD		
<b>D/C metformin when Creatinine &gt;1.5 men or &gt;1.4 women</b>		
<b>Peripheral Neuropathy:</b> Foot ulcers common, check feet each visit, refer to shoe clinic		
<b>Retinopathy:</b> Ophth/retinal visits regularly		
<b>Autonomic Neuropathy:</b> Frequent BP fluctuations, including orthostatic symptoms.		

## Type 2 Diabetes - Chronic Kidney Disease

### Edema/Fluid Overload

Establish patient's dry wt; Titrate furosemide 20-240mg BID (diuresis lasts 6 hours-give AM & mid-day)

### Metabolic Bone Disease

**Evidence Based:** Phosphorus (PO<sub>4</sub>): if >4.6 mg/dL, start binder (calcium); Refer to RD for dietary PO<sub>4</sub> restriction

Calcium (Ca): If <8.4, start/increase calcium supplementation; target: 8.4-9.5 mg/dL

If >10.2, correct causes (often 2° meds), need to hold Ca and/or Vit D/calcitriol

**Consensus Opinion:** If iPTH elevated, measure 25(OH) Vitamin D; If 25(OH)D >=30mg/mL, start calcitriol

If 25(OH) Vitamin D <30mg/mL, start ergocalciferol (Vitamin D2)

Follow Ca, PO<sub>4</sub>, iPTH, and 25(OH)D (Vitamin D): if Ca or PO<sub>4</sub> above target or if iPTH below target, hold calcitriol and/or calcium

CKD Stage	eGFR	iPTH goal	PO <sub>4</sub> Goal	Ca Goal	Ca goal Ca x PO <sub>4</sub>
3	30-59	35-70	2.7-4.6	8.4-9.5	< 55
4	15-29	70-110	2.7-4.6	8.4-9.5	< 55
5	< 15	150-300	3.5-5.4	8.4-9.5	< 55

Medication*	iPTH effect	PO <sub>4</sub> effect	Ca effect	Comments
<b>Phosphate Binders</b>				
<i>CaCO<sub>3</sub> (Oyst-Cal or TUMS) 500-2000mg with meals</i>	–	↓	↑	Use if Ca < 8.4; No more than 7g/d
<i>Ca Acetate 1334-2868mg with meals</i>	–	↓↓	↑	Use if Ca < 8.4 & PO <sub>4</sub> > 5
<i>Sevelamer (Renagel) 800-1600mg TID</i>	–	↓↓		Decrease PO <sub>4</sub> , no effect on Ca; cost
<i>Lanthanum 1500-3750mg/day w/ meals</i>	–	↓↓	↓	Decrease PO <sub>4</sub> and Ca; cost
<i>Aluminum 600-1200mg TID between meals &amp; HS</i>	–	↓↓	–	ONLY if PO <sub>4</sub> > 7 and Ca x PO <sub>4</sub> > 55; not more than 30 days (toxicity)
<b>Vitamin D and Analogs</b>				
<i>Vit D2 (Ergocalciferol) 1.25-5mg daily</i>	↓	–	↑↑	Use if Vit D < 30 mg/mL
<i>Calcitriol 0.25-1mcg daily or 0.5-3mcg TIW</i>	↓	–	↑↑	Use only if Ca & PO <sub>4</sub> in normal range
<i>Doxercalciferol 1-3mcg daily or 10-20mcg TIW</i>	↓	–	↑	Hold if Ca x PO <sub>4</sub> > 55
<b>Other</b>				
<i>Cinacalcet 30-180mg daily</i>	↓	↓	↓↓	Do not use if Ca < 8.4

\*Always include dietary phosphorous restriction

Drugs in italics are not on the IHS National Core Formulary

### Lab Monitoring

Parameter	GFR > 60	GFR 30-59	GFR 15-29	GFR<15 not on Dialysis
Creatinine and eGFR	Annual	Each visit	Each visit	Each visit
UACR	Annual	Q3-6mos*	Each visit*	Each visit*
Hb	Annual	Q3mos	Q3mos	Q3mos
Fe, Transferrin Sat, Ferritin		Q3mos	Q3mos	Q3mos
Ca, PO <sub>4</sub> , and iPTH		At least annually	Q3mos	Q3mos

**Monitor more often if values are worsening or on medications that affect these labs**

\*Frequency of checking depends on rate of rise of urine albumin

Ref: KDOQI/NKF and UK Renal Assoc 4th Ed. Clinical Practice Guidelines for Complications of CKD  
 ADA Clinical Practice Recommendations 2010. J Am Soc Nephrol 2010; 21:2-6.